Overview

ABRAXANE is an albumin-bound form of paclitaxel

ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)

Visual representation based on preclinical evidence.

  • ABRAXANE is a microtubule inhibitor
  • ABRAXANE contains albumin (human), a derivative of human blood, and has a mean particle size of approximately 130 nanometers
Pharmacokinetics of ABRAXANE

Overview

ABRAXANE is an albumin-bound form of paclitaxel

  • ABRAXANE is a microtubule inhibitor
  • ABRAXANE contains albumin (human), a derivative of human blood, and has a mean particle size of approximately 130 nanometers
Pharmacokinetics of ABRAXANE
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)
Visual representation based on preclinical evidence.

INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine

INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine